Discover open access scientific publications

Search, annotate, share and cite publications

Publications by J. W. Kolaczynski

Continuous Subcutaneous Insulin Infusion (CSII) of Insulin Aspart Versus Multiple Daily Injection of Insulin Aspart/Insulin Glargine in Type 1 Diabetic Patients Previously Treated With CSII

Diabetes Care
Internal MedicineEndocrinologyAdvancedMetabolismSpecialized NursingDiabetes
2005English

Related publications

HbA1c Variability in Adults With Type 1 Diabetes on Continuous Subcutaneous Insulin Infusion (CSII) Therapy Compared to Multiple Daily Injection (MDI) Treatment

BMJ Open
Medicine
2019English

Clinical Performance of CGMS in Type 1 Diabetic Patients Treated by Continuous Subcutaneous Insulin Infusion Using Insulin Analogs

Diabetes Care
Internal MedicineEndocrinologyAdvancedMetabolismSpecialized NursingDiabetes
2003English

Safety, Immunogenicity and Glycemic Control of Insulin Aspart Biosimilar SAR341402 Versus Originator Insulin Aspart in People With Diabetes Also Using Insulin Glargine: 12-Month Results From the GEMELLI 1 Trial

Diabetes Technology and Therapeutics
MedicineEndocrinologyMedical Laboratory TechnologyMetabolismDiabetes
2020English

Efficacy and Safety of LY2963016 Insulin Glargine in Patients With Type 1 and Type 2 Diabetes Previously Treated With Insulin Glargine

Diabetes, Obesity and Metabolism
Internal MedicineEndocrinologyMetabolismDiabetes
2016English

Improved Postprandial Glucose With Inhaled Technosphere Insulin Compared With Insulin Aspart in Patients With Type 1 Diabetes on Multiple Daily Injections: The STAT Study

Diabetes Technology and Therapeutics
MedicineEndocrinologyMedical Laboratory TechnologyMetabolismDiabetes
2018English

Continuous Subcutaneous Insulin Infusion

Diabetes Care
Internal MedicineEndocrinologyAdvancedMetabolismSpecialized NursingDiabetes
1997English

Continuous Subcutaneous Insulin Infusion

Diabetes Care
Internal MedicineEndocrinologyAdvancedMetabolismSpecialized NursingDiabetes
2002English

Comparison of a Soluble Co-Formulation of Insulin Degludec/Insulin Aspart vs Biphasic Insulin Aspart 30 in Type 2 Diabetes: A Randomised Trial

European Journal of Endocrinology
MedicineEndocrinologyMetabolismDiabetes
2012English

Insulin Aspart Reduziert Kardiovaskuläre Ereignisse

MMW Fortschritte der Medizin
Medicine
2016English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy